Sanofi ROE 2006-2018 | SNY

Current and historical return on equity (ROE) values for Sanofi (SNY) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Sanofi ROE for the three months ending March 31, 2018 was 18.18%.
Sanofi ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2018-03-31 $4.71B $0.00B 14.55%
2017-12-31 $9.53B $65.85B 29.46%
2017-09-30 $9.90B $0.00B 31.05%
2017-06-30 $9.92B $63.58B 31.13%
2017-03-31 $10.09B $0.00B 32.21%
2016-12-31 $5.21B $63.88B 16.64%
2016-09-30 $6.19B $0.00B 40.31%
2016-06-30 $5.76B $61.39B 18.55%
2016-03-31 $5.52B $0.00B 16.49%
2015-09-30 $4.90B $0.00B 9.45%
2015-06-30 $4.59B $62.80B 6.57%
2014-06-30 $5.57B $71.01B 10.27%
2013-06-30 $6.39B $73.39B 11.39%
2012-06-30 $8.61B $72.42B 22.81%
2012-03-31 $8.56B $0.00B 22.19%
2011-12-31 $9.33B $78.54B 24.20%
2011-09-30 $8.04B $0.00B 21.95%
2011-06-30 $7.45B $75.69B 20.36%
2011-03-31 $8.22B $0.00B 23.85%
2010-12-31 $8.24B $70.76B 23.90%
2010-09-30 $9.30B $0.00B 27.63%
2010-06-30 $10.37B $67.09B 30.81%
2010-03-31 $11.38B $0.00B 35.40%
2009-12-31 $10.99B $67.56B 34.20%
2009-09-30 $9.57B $0.00B 30.08%
2009-06-30 $8.26B $61.00B 25.94%
2009-03-31 $7.76B $0.00B 23.66%
2008-12-31 $7.76B $66.31B 23.68%
2008-09-30 $9.72B $0.00B 30.82%
2008-06-30 $10.42B $64.83B 33.04%
2008-03-31 $9.21B $0.00B 29.84%
2007-12-31 $8.40B $61.30B 27.21%
2007-09-30 $6.95B $0.00B 23.22%
2007-06-30 $6.45B $62.17B 21.56%
2007-03-31 $7.18B $0.00B 25.15%
2006-12-31 $6.99B $57.56B 24.47%
2006-09-30 $6.79B $0.00B 23.61%
2006-06-30 $6.95B $56.70B 24.18%
2006-03-31 $6.66B $0.00B 23.26%
2005-12-31 $5.54B $58.32B 19.34%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $111.886B $39.599B
Sanofi-Aventis is a global pharmaceutical company that contributes to enhance life by providing medicines, vaccines, and integrated healthcare solutions adapted to local needs and means primarily in Europe and the United States. The company is engaged in the research, development, manufacture and marketing of healthcare products. Its strategy is built around three priorities to reach its goals and ensure sustainable growth. The priorities are: increasing innovation in Research and Development, adapting Group structures to future challenges and seizing external growth opportunities. Sanofi-Aventis specializes in six therapeutic areas: thrombosis, cardiovascular, metabolic disorders, oncology, central nervous system (CNS) and internal medicine. The Company offers vaccines in five areas: pediatric combination vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines. Sanofi-Aventis is headquartered in Paris, France.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $390.684B 18.32
Pfizer (PFE) United States $262.581B 14.80
Novartis AG (NVS) Switzerland $204.469B 17.47
Merck (MRK) United States $201.378B 17.45
AbbVie (ABBV) United States $134.913B 11.98
Eli Lilly (LLY) United States $119.915B 21.08
Novo Nordisk (NVO) Denmark $108.835B 17.67
AstraZeneca (AZN) United Kingdom $103.621B 12.86
GlaxoSmithKline (GSK) United Kingdom $101.752B 13.68
Bristol-Myers Squibb (BMY) United States $86.262B 14.21